Morphological features of IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 13, 2017, Pages E2598-E2607

  Klinker, Matthew W ^a   Marklein, Ross A ^a   Lo Surdo, Jessica L ^a   Wei, Cheng Hong ^a   Bauer, Steven R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

High content imaging; Immunosuppression; Interferon gamma; Mesenchymal stromal cells; Morphology

Indexed keywords

GAMMA INTERFERON;

ARTICLE; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; T LYMPHOCYTE ACTIVATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT;

FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSION; IN VITRO TECHNIQUES; INTERFERON-GAMMA; MESENCHYMAL STROMAL CELLS; PRINCIPAL COMPONENT ANALYSIS;

EID: 85016439461     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1617933114     Document Type: Article

References (59)

1. Klinker MW, Wei C-H (2015) Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells 7(3):556-567.
2. English K (2013) Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91(1):19-26.
3. Sharma RR, Pollock K, Hubel A, McKenna D (2014) Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion 54(5): 1418-1437.
4. Griffin MD, et al. (2013) Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? Stem Cells 31(10): 2033-2041.
5. Galipeau J, et al. (2016) International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18(2):151-159.
6. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT) (2013) Immunological characterization of multipotent mesenchymal stromal cells - The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15(9):1054-1061.
7. Rizzo R, et al. (2011) A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. Cytotherapy 13(5):523-527.
8. Salem B, et al. (2015) Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. Cytotherapy 17(12): 1675-1686.
9. Copland I, Qayed M, Garcia M, Galipeau J, Waller E (2015) Bone marrow mesenchymal stromal cells from patients with acute and chronic graft-versus-host disease deploy normal phenotype, differentiation plasticity, and immune-suppressive activity. Biol Blood Marrow Transplant 21(5):934-940.
10. Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR (2014) MSC-based product characterization for clinical trials: An FDA perspective. Cell Stem Cell 14(2):141-145.
11. Dominici M, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-317.
12. Marklein RA, et al. (2016) High content imaging of early morphological signatures predicts long term mineralization capacity of human mesenchymal stem cells upon osteogenic induction. Stem Cells 34(4):935-947.
13. Dazzi F, Krampera M (2011) Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol 24(1):49-57.
14. Valencic E, Piscianz E, Andolina M, Ventura A, Tommasini A (2010) The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. Cytotherapy 12(2):154-160.
15. Matsuoka F, et al. (2013) Morphology-based prediction of osteogenic differentiation potential of human mesenchymal stem cells. PLoS One 8(2):e55082.
16. Treiser MD, et al. (2010) Cytoskeleton-based forecasting of stem cell lineage fates. Proc Natl Acad Sci USA 107(2):610-615.
17. Chen D, et al. (2016) Machine learning based methodology to identify cell shape phenotypes associated with microenvironmental cues. Biomaterials 104:104-118.
18. Krampera M, et al. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2):386-398.
19. Meisel R, et al. (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12):4619-4621.
20. Solchaga LA, Zale EA (2012) Prostaglandin E2: A putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am J Stem Cells 1(2): 138-145.
21. Phinney DG (2007) Biochemical heterogeneity of mesenchymal stem cell populations: Clues to their therapeutic efficacy. Cell Cycle 6(23):2884-2889.
22. Ho AD, Wagner W, Franke W (2008) Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10(4):320-330.
23. Phinney DG (2012) Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy. J Cell Biochem 113(9):2806-2812.
24. Galipeau J, Krampera M (2015) The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 17(2):125-127.
25. Kim HP, Imbert J, Leonard WJ (2006) Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 17(5):349-366.
26. Liao W, Lin JX, LeonardWJ (2011) IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 23(5):598-604.
27. Bloom DD, et al. (2015) A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cytotherapy 17(2):140-151.
28. Ketterl N, et al. (2015) A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther 6:236.
29. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57(1):11-20.
30. Viswanathan S, et al. (2014) Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev 23(11):1157-1167.
31. Polchert D, et al. (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38(6):1745-1755.
32. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P (2010) Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 12(1):R31.
33. Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591.
34. Frausto-Del-Río D, et al. (2012) Interferon gamma induces actin polymerization, Rac1 activation and down regulates phagocytosis in human monocytic cells. Cytokine 57(1): 158-168.
35. Chen Z, et al. (2011) Negative regulation of interferon-γ/STAT1 signaling through cell adhesion and cell density-dependent STAT1 dephosphorylation. Cell Signal 23(8):1404-1412.
36. Chinnadurai R, Copland IB, Patel SR, Galipeau J (2014) IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol 192(4):1491-1501.
37. Zimmermann JA, McDevitt TC (2014) Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. Cytotherapy 16(3):331-345.
38. Lo Surdo JL, Millis BA, Bauer SR (2013) Automated microscopy as a quantitative method to measure differences in adipogenic differentiation in preparations of human mesenchymal stromal cells. Cytotherapy 15(12):1527-1540.
39. Lee WC, et al. (2014) Multivariate biophysical markers predictive of mesenchymal stromal cell multipotency. Proc Natl Acad Sci USA 111(42):E4409-E4418.
40. Whitfield MJ, Lee WC, Van Vliet KJ (2013) Onset of heterogeneity in culture-expanded bone marrow stromal cells. Stem Cell Res (Amst) 11(3):1365-1377.
41. Lo Surdo JL (2013) Toward improved characterization of human mesenchymal stem cells for use in cellular therapies: A regulatory science perspective. PhD dissertation (University of Pittsburgh, Pittsburgh).
42. Lv F-J, Tuan RS, Cheung KM, Leung VY (2014) Concise review: The surface markers and identity of human mesenchymal stem cells. Stem Cells 32(6):1408-1419.
43. Pajerowski JD, Dahl KN, Zhong FL, Sammak PJ, Discher DE (2007) Physical plasticity of the nucleus in stem cell differentiation. Proc Natl Acad Sci USA 104(40):15619-15624.
44. Talwar S, Kumar A, Rao M, Menon GI, Shivashankar GV (2013) Correlated spatiotemporal fluctuations in chromatin compaction states characterize stem cells. Biophys J 104(3):553-564.
45. Shin J-W, et al. (2013) Mechanobiology of bone marrow stem cells: From myosin-II forces to compliance of matrix and nucleus in cell forms and fates. Differentiation 86(3):77-86.
46. Chambliss AB, Wu P-H, Chen W-C, Sun SX, Wirtz D (2013) Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution. FASEB J 27(7):2667-2676.
47. Rovira Gonzalez YI, Lynch PJ, Thompson EE, Stultz BG, Hursh DA (2016) In vitro cytokine licensing induces persistent permissive chromatin at the indoleamine 2,3-dioxygenase promoter. Cytotherapy 18(9):1114-1128.
48. Stultz BG, et al. (2016) Chromosomal stability of mesenchymal stromal cells during in vitro culture. Cytotherapy 18(3):336-343.
49. Colter DC, Sekiya I, Prockop DJ (2001) Identification of a subpopulation of rapidly selfrenewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 98(14):7841-7845.
50. Prockop DJ, Sekiya I, Colter DC (2001) Isolation and characterization of rapidly selfrenewing stem cells from cultures of human marrow stromal cells. Cytotherapy 3(5): 393-396.
51. Sekiya I, et al. (2002) Expansion of human adult stem cells from bone marrow stroma: Conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 20(6):530-541.
52. Fienberg HG, Nolan GP, eds (2014) High-Dimensional Single Cell Analysis (Springer, Berlin), Vol 377.
53. Rennerfeldt DA, Van Vliet KJ (2016) When colonies are not clones: Evidence and implications of intracolony heterogeneity in mesenchymal stem cells. Stem Cells 34(5): 1135-1141.
54. Phadnis SM, et al. (2015) Dynamic and social behaviors of human pluripotent stem cells. Sci Rep 5:14209.
55. Prockop DJ, Phinney D, Bunnell B (2008) Mesenchymal Stem Cells - Methods and Protocols. Methods in Molecular Biology (Humana, Totowa, NJ), Vol 449.
56. Bellayr IH, et al. (2014) Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Res Ther 5(2):59.
57. Bellayr IH, Marklein RA, Lo Surdo JL, Bauer SR, Puri RK (2016) Identification of predictive gene markers for multipotent stromal cell proliferation. Stem Cells Dev 25(11): 861-873.
58. Mindaye ST, Ra M, Lo Surdo JL, Bauer SR, Alterman MA (2013) Global proteomic signature of undifferentiated human bone marrow stromal cells: Evidence for donorto-donor proteome heterogeneity. Stem Cell Res (Amst) 11(2):793-805.
59. Carpenter A, et al. (2006) CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7(Software):R100.